Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

REFLECT: Reproductive Education and Fertility Links for Cancer Treatment

Recruiting

Conditions: Reproductive Behavior

Interventions: Behavioral: REFLECT web-based tool

First Posted Date: 2024-01-10

Last Posted Date: 2025-05-14

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT06199726

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Biological: MSGV1-PSCA-8T28Z
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2024-01-05

Last Posted Date: 2025-06-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 30

Registration Number: NCT06193486

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Phase 2

Recruiting

Conditions: Acute Lymphoblastic Leukemia
B-Cell Lymphoblastic Leukemia

Interventions: Drug: Tecartus

First Posted Date: 2023-11-22

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 60

Registration Number: NCT06144606

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Non-Invasive Biomarkers in Prostate Cancer Disease Management

Recruiting

Conditions: Prostate Cancer

Interventions: Genetic: Genomic and Histological Evaluation

First Posted Date: 2023-11-22

Last Posted Date: 2025-04-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 500

Registration Number: NCT06144619

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Pilot Trial of Adaptive Radiotherapy Boost for HNSCC

Not Applicable

Recruiting

Conditions: Squamous Cell Carcinoma
Head and Neck Cancer

Interventions: Radiation: Intensity-modulated radiotherapy
Other: Magnetic Resonance Guidance

First Posted Date: 2023-11-18

Last Posted Date: 2025-06-19

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT06137274

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

Phase 2

Recruiting

Conditions: Metastatic Uveal Melanoma

Interventions: Drug: ZIV-Aflibercept
Drug: Cemiplimab

First Posted Date: 2023-11-07

Last Posted Date: 2025-05-07

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 32

Registration Number: NCT06121180

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Phase 2

Recruiting

Conditions: GastroEsophageal Cancer
Gastric Cancer

Interventions: Drug: Neratinib
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: 5-Fluorouracil + leucovorin
Drug: Pembrolizumab

First Posted Date: 2023-10-31

Last Posted Date: 2025-04-17

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 36

Registration Number: NCT06109467

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Phase 2

Recruiting

Conditions: Large B-cell Lymphoma
Relapsed Non-Hodgkin Lymphoma

Interventions: Radiation: Comprehensive Ablative Bridging Irradiation (CABI)
Biological: Chimeric Antigen Receptor T-Cell Therapy

First Posted Date: 2023-10-27

Last Posted Date: 2025-06-12

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT06104592

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

App for Reducing Cravings to Smoke

Phase 2

Recruiting

Conditions: Smoking

Interventions: Behavioral: Quitline Services
Behavioral: Updating Existing Smartphone App
Behavioral: Quitline Services and Smartphone App

First Posted Date: 2023-10-18

Last Posted Date: 2025-04-20

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 3600

Registration Number: NCT06088498

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response

Not Applicable

Active, not recruiting

Conditions: Pancreatic Cancer

Interventions: Behavioral: Quality fo Life Questionnaire (FHSI)
Behavioral: Vioscreen Food Frequency Questionnaire (FFQ)
Behavioral: Educational Handouts
Behavioral: NutritionCoaching
Behavioral: Follow-Up Survey
Behavioral: Functional Assessment of Anorexia/Cachexia Treatment (FAACT) Questionnaire
Behavioral: Patient Reported Outcomes Measure- Cognitive Function (PROMIS-Cog) Questionnaire

First Posted Date: 2023-09-22

Last Posted Date: 2025-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 40

Registration Number: NCT06050395

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy